IL314022A - Methods of treating idiopathic pulmonary fibrosis with deupirfenidone - Google Patents
Methods of treating idiopathic pulmonary fibrosis with deupirfenidoneInfo
- Publication number
- IL314022A IL314022A IL314022A IL31402224A IL314022A IL 314022 A IL314022 A IL 314022A IL 314022 A IL314022 A IL 314022A IL 31402224 A IL31402224 A IL 31402224A IL 314022 A IL314022 A IL 314022A
- Authority
- IL
- Israel
- Prior art keywords
- subject
- lyt
- treatment
- pirfenidone
- tid
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (16)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263296818P | 2022-01-05 | 2022-01-05 | |
| US202263296843P | 2022-01-05 | 2022-01-05 | |
| US202263296826P | 2022-01-05 | 2022-01-05 | |
| US202263326132P | 2022-03-31 | 2022-03-31 | |
| US202263326129P | 2022-03-31 | 2022-03-31 | |
| US202263341281P | 2022-05-12 | 2022-05-12 | |
| US202263341269P | 2022-05-12 | 2022-05-12 | |
| US202263341279P | 2022-05-12 | 2022-05-12 | |
| US202263341828P | 2022-05-13 | 2022-05-13 | |
| US202263352107P | 2022-06-14 | 2022-06-14 | |
| US202263356653P | 2022-06-29 | 2022-06-29 | |
| US202263374362P | 2022-09-01 | 2022-09-01 | |
| US202263403481P | 2022-09-02 | 2022-09-02 | |
| US202263431530P | 2022-12-09 | 2022-12-09 | |
| US202263432208P | 2022-12-13 | 2022-12-13 | |
| PCT/US2023/060185 WO2023133476A1 (en) | 2022-01-05 | 2023-01-05 | Methods of treating idiopathic pulmonary fibrosis with deupirfenidone |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL314022A true IL314022A (en) | 2024-08-01 |
Family
ID=87074293
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL314022A IL314022A (en) | 2022-01-05 | 2023-01-05 | Methods of treating idiopathic pulmonary fibrosis with deupirfenidone |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20240358690A1 (enExample) |
| EP (1) | EP4460305A4 (enExample) |
| JP (1) | JP2025502023A (enExample) |
| KR (1) | KR20240131352A (enExample) |
| AU (1) | AU2023205787A1 (enExample) |
| CA (1) | CA3239301A1 (enExample) |
| IL (1) | IL314022A (enExample) |
| MX (1) | MX2024008476A (enExample) |
| WO (1) | WO2023133476A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023192646A1 (en) * | 2022-03-31 | 2023-10-05 | Puretech Lyt 100, Inc. | Methods of treating fibrotic- and collagen-mediated diseases and disorders with deupirfenidone |
| WO2026133158A1 (en) * | 2024-12-16 | 2026-06-25 | Puretech Lyt 100, Inc. | Deupirfenidone for use for treating interstitial lung diseases and other fibrotic-mediated pulmonary diseases |
| WO2026133157A1 (en) * | 2024-12-16 | 2026-06-25 | Puretech Lyt 100, Inc. | Deupirfenidone for use for treating idiopathic pulmonary fibrosis |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080287508A1 (en) * | 2007-05-18 | 2008-11-20 | Intermune, Inc. | Altering pharmacokinetics of pirfenidone therapy |
| AU2008265595B2 (en) * | 2007-06-20 | 2014-12-04 | PureTech LYT 100 Inc. | Substituted N-Aryl pyridinones as fibrotic inhibitors |
| US20090131485A1 (en) * | 2007-09-10 | 2009-05-21 | Concert Pharmaceuticals, Inc. | Deuterated pirfenidone |
| IL319182A (en) * | 2018-09-14 | 2025-04-01 | Puretech Lyt 100 Inc | Deuterium-enriched pirfenidone and methods of using it |
| US20250114341A1 (en) * | 2018-09-14 | 2025-04-10 | Puretech Lyt 100, Inc. | Methods of treating idiopathic pulmonary fibrosis with deupirfenidone |
| US20230129866A1 (en) * | 2020-03-13 | 2023-04-27 | Puretech Lyt 100, Inc. | Methods of treating respiratory disease with deupirfenidone |
-
2023
- 2023-01-05 AU AU2023205787A patent/AU2023205787A1/en active Pending
- 2023-01-05 KR KR1020247022244A patent/KR20240131352A/ko active Pending
- 2023-01-05 CA CA3239301A patent/CA3239301A1/en active Pending
- 2023-01-05 MX MX2024008476A patent/MX2024008476A/es unknown
- 2023-01-05 IL IL314022A patent/IL314022A/en unknown
- 2023-01-05 WO PCT/US2023/060185 patent/WO2023133476A1/en not_active Ceased
- 2023-01-05 EP EP23737759.3A patent/EP4460305A4/en active Pending
- 2023-01-05 JP JP2024540710A patent/JP2025502023A/ja active Pending
-
2024
- 2024-06-28 US US18/758,783 patent/US20240358690A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2025502023A (ja) | 2025-01-24 |
| US20240358690A1 (en) | 2024-10-31 |
| AU2023205787A1 (en) | 2024-06-13 |
| WO2023133476A1 (en) | 2023-07-13 |
| EP4460305A1 (en) | 2024-11-13 |
| EP4460305A4 (en) | 2025-12-31 |
| CA3239301A1 (en) | 2023-07-13 |
| KR20240131352A (ko) | 2024-08-30 |
| MX2024008476A (es) | 2024-07-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240358690A1 (en) | Methods of treating idiopathic pulmonary fibrosis with deupirfenidone | |
| Cobos et al. | Dermatomyositis: An Update on Diagnosis and Treatment: GA Cobos et al. | |
| EP3823623B1 (en) | A substituted amino-pyrimidine compound for use in a method for treatment and prevention of multiple sclerosis | |
| US12622899B2 (en) | Methods of treating idiopathic pulmonary fibrosis with deupirfenidone | |
| US20230210845A1 (en) | Dosing methods for treatment of cardiovascular conditions | |
| CN110536684A (zh) | 三联组合制剂以及治疗心血管疾病或降低心血管疾病风险的方法 | |
| KR20220011652A (ko) | 브루톤 타이로신 키나제 저해제를 사용하여 쇼그렌 증후군을 치료하는 방법 | |
| US20220409620A1 (en) | Reducing immunogenicity to pegloticase | |
| Boettcher et al. | Vericiguat in combination with short‐acting nitroglycerin in patients with chronic coronary syndromes: the randomized, phase Ib, VENICE study | |
| US20250249001A1 (en) | Methods of treating substance use disorder with 4-(3-cyanophenyl)-6-pyridinylpyrimidine mglu5 negative allosteric modulators | |
| McNicholl et al. | Omalizumab: the evidence for its place in the treatment of allergic asthma | |
| US20250114340A1 (en) | Methods of treating interstitial lung diseases and other fibrotic-mediated pulmonary diseases and disorders with deupirfenidone | |
| CN118510510A (zh) | 用氘吡非尼酮治疗特发性肺纤维化的方法 | |
| HK40114519A (en) | Methods of treating idiopathic pulmonary fibrosis with deupirfenidone | |
| US20210137903A1 (en) | Anti-androgens for the treatment of prostrate cancer | |
| TW202237078A (zh) | 使用德弗米司特(devimistat)治療肉瘤之治療方法及組合物 | |
| DEVELOPM | Drug DeveloPment | |
| US20230381190A1 (en) | Methods and Treatment for Complex Lymphatic Malformations | |
| KR20260056206A (ko) | 국소 분절 사구체경화증을 치료하기 위한 trpc6의 억제제 | |
| TW202535397A (zh) | 給藥方案 | |
| EA051453B1 (ru) | Способы лечения и профилактики рассеянного склероза с применением соединений замещенного аминопиримидина | |
| WO2020144646A1 (en) | Apalutamide dispersed in applesauce for treating prostate cancer | |
| WO2023229605A1 (en) | Methods and treatment for complex lymphatic malformations | |
| Heller et al. | RESOLVE Protocol Safety, Tolerability and Efficacy of Sofosbuvir, Velpatasvir, and Voxilaprevir in Subjects with previous DAA experience | |
| TW202537625A (zh) | 使用布魯頓酪胺酸激酶抑制劑治療慢性自發性蕁麻疹之方法 |